Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02TGD
|
||||
| Former ID |
DCL000897
|
||||
| Drug Name |
Netoglitazone
|
||||
| Synonyms |
Isaglitazone; Netoglitazone [USAN]; MCC 555; MCC-555; RWJ-241947; Netoglitazone (USAN/INN); 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; 5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione; 5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]-1,3-thiazolidine-2,4-dione
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Mitsubishi Pharma
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H16FNO3S
|
||||
| InChI |
InChI=1S/C21H16FNO3S/c22-18-4-2-1-3-16(18)12-26-17-8-7-14-9-13(5-6-15(14)11-17)10-19-20(24)23-21(25)27-19/h1-9,11,19H,10,12H2,(H,23,24,25)
|
||||
| InChIKey |
PKWDZWYVIHVNKS-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 161599-99-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10266079, 12014903, 14804654, 30409351, 47206874, 53789988, 56314529, 57399414, 78102491, 103302827, 104438295, 126455542, 127315825, 127315826, 127315827, 127315828, 127315829, 127334948, 127334949, 127334950, 127334951, 127334952, 134224278, 134339349, 134339958, 135178649, 135650709, 137063230, 140097400, 143170090, 162222887, 176225523, 179150029, 215780839, 223704978, 223908693, 226509499, 252450244, 252543600
|
||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor gamma | Target Info | Modulator | [552545] | |
| PANTHER Pathway | CCKR signaling map ST | ||||
| WikiPathways | Wnt Signaling Pathway Netpath | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Differentiation of white and brown adipocyte | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| Adipogenesis | |||||
| SREBP signalling | |||||
| Nuclear Receptors | |||||
| References | |||||
| Ref 536649 | Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. | ||||
| Ref 539767 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2707). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.